Ionis Pharmaceuticals, Inc. (IONS)
IONS Stock Price Chart
Explore Ionis Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze IONS price movements and trends.
IONS Company Profile
Discover essential business fundamentals and corporate details for Ionis Pharmaceuticals, Inc. (IONS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 May 1991
Employees
1.07k
Website
https://www.ionispharma.comCEO
Brett Monia
Description
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
IONS Financial Timeline
Browse a chronological timeline of Ionis Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$1.10, while revenue estimate is $187.14m.
Earnings released on 29 Apr 2026
EPS came in at -$0.56 surpassing the estimated -$0.85 by +34.12%, while revenue for the quarter reached $246.00m , beating expectations by +25.79%.
Earnings released on 25 Feb 2026
EPS came in at -$1.41 falling short of the estimated -$1.24 by -14.02%, while revenue for the quarter reached $203.00m , beating expectations by +30.07%.
Earnings released on 29 Oct 2025
EPS came in at -$0.61 surpassing the estimated -$1.15 by +46.96%, while revenue for the quarter reached $156.72m , beating expectations by +2.05%.
Earnings released on 30 Jul 2025
EPS came in at $0.86 surpassing the estimated $0.27 by +218.52%, while revenue for the quarter reached $452.05m , beating expectations by +243.12%.
Earnings released on 30 Apr 2025
EPS came in at -$0.75 surpassing the estimated -$1.11 by +32.43%, while revenue for the quarter reached $131.61m , missing expectations by -12.60%.
Earnings released on 19 Feb 2025
EPS came in at -$0.66 surpassing the estimated -$1.09 by +39.45%, while revenue for the quarter reached $226.58m , beating expectations by +72.78%.
Earnings released on 6 Nov 2024
EPS came in at -$0.95 surpassing the estimated -$1.16 by +18.10%, while revenue for the quarter reached $133.81m , missing expectations by -7.36%.
Earnings released on 1 Aug 2024
EPS came in at -$0.45 surpassing the estimated -$0.92 by +51.09%, while revenue for the quarter reached $225.25m , beating expectations by +50.10%.
Earnings released on 7 May 2024
EPS came in at -$0.98 surpassing the estimated -$1.05 by +6.44%, while revenue for the quarter reached $119.00m , missing expectations by -9.45%.
Earnings released on 21 Feb 2024
EPS came in at -$0.06 surpassing the estimated -$0.83 by +92.77%, while revenue for the quarter reached $324.51m , beating expectations by +85.69%.
Earnings released on 2 Nov 2023
EPS came in at -$1.03 surpassing the estimated -$1.04 by +0.96%, while revenue for the quarter reached $144.21m , beating expectations by +8.51%.
Earnings released on 9 Aug 2023
EPS came in at -$0.60 surpassing the estimated -$0.90 by +33.33%, while revenue for the quarter reached $188.41m , beating expectations by +35.71%.
Earnings released on 3 May 2023
EPS came in at -$0.87 surpassing the estimated -$0.91 by +4.40%, while revenue for the quarter reached $130.52m , missing expectations by -7.11%.
Earnings released on 22 Feb 2023
EPS came in at -$0.37 surpassing the estimated -$1.06 by +65.09%, while revenue for the quarter reached $151.89m , missing expectations by -5.14%.
Earnings released on 9 Nov 2022
EPS came in at -$0.33 surpassing the estimated -$0.74 by +55.41%, while revenue for the quarter reached $159.77m , beating expectations by +10.99%.
Earnings released on 9 Aug 2022
EPS came in at -$0.74 falling short of the estimated -$0.62 by -19.35%, while revenue for the quarter reached $133.79m , missing expectations by -4.80%.
Earnings released on 4 May 2022
EPS came in at -$0.46 surpassing the estimated -$0.71 by +35.21%, while revenue for the quarter reached $141.92m , beating expectations by +15.89%.
Earnings released on 24 Feb 2022
EPS came in at $1.41 surpassing the estimated $0.28 by +403.57%, while revenue for the quarter reached $440.01m , beating expectations by +59.68%.
Earnings released on 3 Nov 2021
EPS came in at -$0.58 falling short of the estimated -$0.53 by -9.43%, while revenue for the quarter reached $133.09m , missing expectations by -18.68%.
Earnings released on 4 Aug 2021
EPS came in at -$0.57 surpassing the estimated -$0.60 by +5.00%, while revenue for the quarter reached $125.75m , missing expectations by -0.20%.
IONS Stock Performance
Access detailed IONS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
